menu
    • menu
    [{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Annexon Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Redmile Group","highestDevelopmentStatusID":"7","companyTruncated":"Annexon Biosciences \/ Redmile Group"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ANX005","moa":"C1q","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ANX007","moa":"C1q","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"ANX009","moa":"C1q","graph1":"Immunology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ANX005","moa":"C1q","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ANX005","moa":"C1q","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ANX007","moa":"C1q","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ANX005","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ANX007","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ANX005","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ANX007","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ANX007","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"ANX007","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Annexon Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ANX1502","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.13,"dosageForm":"","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ANX005","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ANX007","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Annexon Biosciences

    Menu

    Annexon Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

                            Details : ANX007 is a Fab antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway, for the treatment of Geographic Atrophy.

                            Brand Name : ANX007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 05, 2024

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX005

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Annexon Announces Pricing of $125 Million Underwritten Public Offering

                            Details : The net proceeds will be used to advance the clinical development of late-stage product ANX005, which is being evaluated for the treatment of guillain-barre syndrome.

                            Brand Name : ANX005

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 05, 2024

                            Lead Product(s) : ANX005

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX005

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Annexon Announces Proposed Public Offering of Common Stock

                            Details : The net proceeds will be used to advance the clinical development of late-stage product ANX005, which is being evaluated for the treatment of guillain-barre syndrome.

                            Brand Name : ANX005

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 04, 2024

                            Lead Product(s) : ANX005

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX005

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Annexon: Positive Phase 3 Results for ANX005 in Guillain-Barré Syndrome

                            Details : ANX005 is a mAb designed to fully block C1q and the entire classical complement pathway to preserve functioning synapses to slow neurodegeneration. It is being evaluated for GBS autoimmune disoder.

                            Brand Name : ANX005

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 04, 2024

                            Lead Product(s) : ANX005

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision P...

                            Details : ANX007 is a fragment antigen-binding (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway. It is under phase 2 clinical development for the treatment of Geographic ...

                            Brand Name : ANX007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

                            Details : The net proceeds will be used to advance the global registrational program for ANX007, a fragment antigen-binding antibody designed as a first-in-kind therapeutic to selectively inhibit C1q and a key driver of neurodegeneration, in geographic atrophy.

                            Brand Name : ANX007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 20, 2023

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX1502

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pat...

                            Details : ANX1502 is a classical complement pathway inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of patients with cold agglutinin disease.

                            Brand Name : ANX1502

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : ANX1502

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

                            Details : ANX007 is a fragment antigen-binding (fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway, and a key driver of neurodegeneration.

                            Brand Name : ANX007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 24, 2023

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX005

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS...

                            Details : ANX005 is a a monoclonal antibody (mAb) designed to fully block C1q and the entire classical complement pathway with the aim of preserving functioning synapses to slow or halt neurodegeneration. It is beig evaluated for GBS autoimmune disoder.

                            Brand Name : ANX005

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 10, 2023

                            Lead Product(s) : ANX005

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Annexon Biosciences

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Sign...

                            Details : ANX007 represents the first complement therapeutic candidate to preserve visual acuity, demonstrating a statistically significant reduction of vision loss in both foveal and non-foveal patients at 12 months.

                            Brand Name : ANX007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 24, 2023

                            Lead Product(s) : ANX007

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth